ArticleBMC cancer2025
Study of plasma exosomal miRNAs as novel biomarkers for differentiating primary central nervous system lymphoma and glioblastoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- A novel minimally invasive diagnostic approach of various brain malignancies based on differential miRNA expression.Journal of neuro-oncology · 2026Article
- MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.Discover oncology · 2026Review
- Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- Unraveling Let-7f in oncology: a tumor suppressor with emerging clinical significance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Preoperative diagnosis of the nature of PCNSL is crucial for distinguishing it from commonly confused intracranial gliomas, such as glioblastoma multiforme (GBM). The present research aims to sequence peripheral blood exosomal miRNAs from PCNSL and GBM patients, and to identify the discriminative miRNAs with high feasibility. Plasma exosomal RNAs were extracted, and miRNA sequencing was performed. The miRNAs with significant differences were validated by RT-qPCR. A total of 67 miRNAs were significantly different between the PCNSL and GBM groups. Twenty-seven PCNSL and 27 GBM patients were enrolled for the RT-qPCR validation of 10 selected differentially expressed miRNAs. The expression levels of plasma exosomal hsa-miR-148a-3p, hsa-let-7f-5p, hsa-miR-345-5p and hsa-miR-4433b-5p were upregulated in the PCNSL group compared with those in the GBM group (P = 0.019, P = 0.036, P = 0.009, and P = 0.001, respectively). The combined panel comprising hsa-miR-148a-3p, hsa-miR-345-5p, and hsa-miR-4433b-5p demonstrated significantly enhanced diagnostic performance, with an area under the ROC curve (AUC) of 0.791. Immunohistochemistry analysis revealed that the expression level of EGFR in PCNSL was significantly lower than that in GBM. Western blot and RT-qPCR analysis of EGFR expression levels in LN229 cells revealed that miR-148a-3p and miR-4433b-5p downregulated EGFR expression. The results of luciferase reporter assay showed that the relative luciferase activity of HEK293T cells transfected with EGFR-WT was notably suppressed by miR-4433b-5p (P < 0.001). In conclusion, the plasma exosomal hsa-miR-148a-3p, hsa-miR-345-5p, and hsa-miR-4433b-5p might be identified as novel biomarkers for differentiating PCNSL and GBM. The increased expression level of EGFR in GBM may be achieved by the negative regulatory effects of miR-4433b-5p. The diagnostic performance of the miRNA biomarkers still needs to be further verified in larger sample size cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.